Cassava Sciences (SAVA) Price & Analysis

Compare

3,853 Followers

SAVA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.15 - $33.98

Previous CloseN/A

Volume2.36M

Average Volume (3M)2.86M

Market Cap

$157.48M

Enterprise Value-$24.94M

Total Cash (Recent Filing)$112.38M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.70

Next Earnings

Nov 05, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Dec 13, 2012

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.92

Shares Outstanding48,307,896

10 Day Avg. Volume7,444,257

30 Day Avg. Volume2,857,223

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.16

Enterprise Value/Revenue-20.41

Enterprise Value/Gross Profit-130.59

Enterprise Value/Ebitda0.20

Forecast

1Y Price Target

$2.00

Price Target Upside-35.48% Downside

Rating ConsensusModerate Sell

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Market DemandThere is an unmet medical need for anti-seizure treatment options, suggesting potential demand for new solutions like simufilam.

New OpportunitiesThe company’s licensing of rights from Yale to an issued patent to use of simufilam as a potential treatment for seizures related to rare neurodevelopment disorders is seen as a positive development.

Bears Say

Clinical TrialsResults from the 76-week ReFocus-ALZ Phase 3 trial with simufilam in patients with mild-to-moderate Alzheimer’s disease did not meet the study’s pre-specified endpoints.

Financial RisksInvestment thesis risks include failure of clinical trials to prove efficacy, regulatory requirements for additional clinical studies, and potential need to raise additional funds under poor market conditions.

Cassava Sciences News

Cassava Sciences (SAVA) Insider Trade Alert! CEO Richard Barry Buys Stock

Cassava Sciences ($SAVA) CEO Richard Barry bought 237,941 shares at prices ranging between $2.13-$2.29 per share, totaling $534,743....

3d ago

SAVA

Cassava Sciences Releases New Corporate Presentation

Cassava Sciences ( ($SAVA) ) has shared an update. Cassava Sciences, Inc. has released a corporate presentation available...

19d ago

SAVA

Cassava Sciences Advances Simufilam for Epilepsy Treatment

Cassava Sciences ( ($SAVA) ) has released its Q2 earnings. Here is a breakdown of the information Cassava...

1M ago

SAVA

Cassava Sciences reports Q2 EPS (92c) vs 13c last year

“2025 has been transformational for Cassava. We have initiated a new program focused on TSC-related epilepsy, a rare...

1M ago

SAVA

Cassava Sciences appoints Hulihan as Chief Medical Officer

Cassava Sciences (SAVA) announced the appointment of Dr. Joseph Hulihan as Chief Medical Officer, CMO. Dr. Hulihan will...

2M ago

SAVA

Cassava Sciences Announces Positive Preclinical Results

Cassava Sciences ( ($SAVA) ) has issued an announcement. On August 4, 2025, Cassava Sciences announced positive preclinical...

2M ago

SAVA

Cassava reports preclinical study on simufilam for TSC-related epilepsy

Cassava Sciences (SAVA) reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of...

2M ago

SAVA

Cassava Sciences Reveals Promising Simufilam Preclinical Data

The latest update is out from Cassava Sciences ( ($SAVA) ). On June 30, 2025, Cassava Sciences announced...

3M ago

SAVA

Cassava Sciences presents poster at TSC 2025 on Simufilam

Cassava Sciences (SAVA) announced that the Company presented a poster at the TSC International Research Conference held June...

3M ago

SAVA

Cassava Sciences Holds 2025 Annual Meeting, Elects Directors

Cassava Sciences ( ($SAVA) ) has shared an update. Cassava Sciences held its 2025 Annual Meeting on May...

4M ago

SAVA

Cassava Sciences Shifts Focus to TSC-Related Epilepsy

Cassava Sciences ( ($SAVA) ) has released its Q1 earnings. Here is a breakdown of the information Cassava...

5M ago

SAVA

Cassava Sciences reports Q1 EPS (48c) vs (43c) last year

“Cassava has made significant progress this year in leveraging our science to expand our portfolio. Our license with...

5M ago

SAVA

Cassava Sciences appoints Bordey as SVP, Neuroscience

Cassava Sciences (SAVA) announced that Angelique Bordey, PhD, has joined the Company as Senior Vice President, SVP, Neuroscience,...

5M ago

SAVA

Cassava Sciences Announces Leadership Changes Amid Strategic Shift

The latest announcement is out from Cassava Sciences ( ($SAVA) ). Cassava Sciences announced the retirement of its...

5M ago

SAVA

SAVA FAQ

What was Cassava Sciences’s price range in the past 12 months?

Cassava Sciences lowest stock price was $1.15 and its highest was $33.98 in the past 12 months.

What is Cassava Sciences’s market cap?

Cassava Sciences’s market cap is $157.48M.

When is Cassava Sciences’s upcoming earnings report date?

Cassava Sciences’s upcoming earnings report date is Nov 05, 2025 which is in 39 days.

How were Cassava Sciences’s earnings last quarter?

Cassava Sciences released its earnings results on Aug 14, 2025. The company reported -$0.92 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.92.

Is Cassava Sciences overvalued?

According to Wall Street analysts Cassava Sciences’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cassava Sciences pay dividends?

Cassava Sciences pays a Notavailable dividend of $5.25 which represents an annual dividend yield of N/A. See more information on Cassava Sciences dividends here

What is Cassava Sciences’s EPS estimate?

Cassava Sciences’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cassava Sciences have?

Cassava Sciences has 48,307,896 shares outstanding.

What happened to Cassava Sciences’s price movement after its last earnings report?

Cassava Sciences reported an EPS of -$0.92 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.702%.

Which hedge fund is a major shareholder of Cassava Sciences?

Currently, no hedge funds are holding shares in SAVA

Cassava Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-88.95%

Trailing 12-Months

Asset Growth

-44.42%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cassava Sciences

Cassava Sciences, Inc. (SAVA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurodegenerative diseases. The company's primary focus is on Alzheimer's disease, with its lead therapeutic product candidate, Simufilam, designed to improve cognitive function in patients. Cassava Sciences also engages in developing diagnostic products for detecting Alzheimer's disease.